Mr. Witty engineered the transaction to reduce Glaxo’s dependence on the risk-laden drug-discovery part of the business, which succeeds or fails on the outcomes of lengthy and expensive clinical trials, patent life cycles and the willingness of governments and health insurers to spend ever-tighter budgets on medicines. By contrast, vaccines and consumer health care are considered more stable businesses.
News 
Market Data 
Discover 
AI
